In the context of target therapies, G12D and G12S KRAS non-small cell lung cancer (NSCLC) patients treated with EGFR TKIs showed promising response rates compared with G12C and G12V KRAS-bearing patients [16]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.